CICLECyclists Inciting Change Through Live Exchange
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
EA Pharma represents the above initiative to "develop biologics and new markers originated in Japan for Crohn's disease by industry-academia collaboration," selected by AMED for CiCLE. In this project, EA Pharma conducts the clinical development of E6011, and the organizations under the joint research agreement (Keio University School of Medicine; Tokyo Medical and Dental University; Kitasato University Kitasato Institute Hospital; Nagoya City University; Kagoshima University and KAN Research Institute, Inc.) conduct the development of new biomarkers.
EA Pharma and Eisai strive to increase treatment benefits for patients with Crohn's disease and their families through quicker development of E6011 via industry- academia-government collaboration, taking the advantage of adoption for CiCLE.
AMED's CiCLE is a grant program to promote the establishment of infrastructure (including human resources) to respond to medical needs and the creation of an environment for open innovation and venture development based on industry- academia-government collaboration.
(19) The arbitration clause, while barring class action suits, allowed Cicle to pursue any claim against Chase in small claims court and provided that if she sought arbitration, the arbitrator could award either party attorney's fees or punitive damages to the extent permissible under the law.
The agreement did not require Cicle's signature, as her assent to its mandatory terms was deemed to be effective when she began using the card.